BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ding L, Ning S, Hu W, Xue Y, Yu S, Ali Sheikh MS. Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-22. [DOI: 10.1155/2022/6595989] [Reference Citation Analysis]
2 Goodwin B, Lou J, Butchy M, Wilson T, Atabek U, Spitz F, Hong Y. Hepatocellular-Cholangiocarcinoma Collision Tumors: An Update of Current Management Practices. The American Surgeon. [DOI: 10.1177/00031348221124323] [Reference Citation Analysis]
3 Prinz C, Frese R, Grams M, Fehring L. Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma. Genes (Basel) 2022;13:1479. [PMID: 36011390 DOI: 10.3390/genes13081479] [Reference Citation Analysis]
4 Wang W, Li J, Liang B, Lv X, Zhu R, Wang J, Huang Z, Yang S, Zhang E. Anatomical liver resection improves surgical outcomes for combined hepatocellular-cholangiocarcinoma: A propensity score matched study. Front Oncol 2022;12:980736. [DOI: 10.3389/fonc.2022.980736] [Reference Citation Analysis]
5 Calderaro J, Di Tommaso L, Maillé P, Beaufrère A, Nguyen CT, Heij L, Gnemmi V, Graham RP, Charlotte F, Chartier S, Wendum D, Vij M, Allende D, Diaz A, Fuster C, Rivière B, Herrero A, Augustin J, Evert K, Calvisi DF, Leow WQ, Wai Leung HH, Bednarsch J, Boleslawski E, Rela M, Wing-Hung Chan A, Forner A, Reig M, Pujals A, Favre L, Allaire M, Scatton O, Uguen A, Trépo E, Sanchez LO, Chatelain D, Remmelink M, Boulagnon-Rombi C, Bazille C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Kather JN, Gouw ASH, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Nault JC, Laurent A, Amaddeo G, Regnault H, de Martin E, Sempoux C, Navale P, Shinde J, Bacchuwar K, Westerhoff M, Cheuk-Lam Lo R, Sebbagh M, Guettier C, Lequoy M, Komuta M, Ziol M, Paradis V, Shen J, Caruso S. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. J Hepatol 2022:S0168-8278(22)02983-X. [PMID: 35987274 DOI: 10.1016/j.jhep.2022.07.019] [Reference Citation Analysis]
6 Hytiroglou P, Bioulac-sage P, Theise ND, Sempoux C. Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms. Cancers 2022;14:3670. [DOI: 10.3390/cancers14153670] [Reference Citation Analysis]
7 Chen Y, Lu Q, Zhu Y, Huang B, Dong Y, Wang W. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics. Ultrasound Med Biol 2022;48:1190-201. [PMID: 35397928 DOI: 10.1016/j.ultrasmedbio.2022.02.014] [Reference Citation Analysis]
8 Zhuravleva E, O'Rourke CJ, Andersen JB. Mutational signatures and processes in hepatobiliary cancers. Nat Rev Gastroenterol Hepatol 2022;19:367-82. [PMID: 35273358 DOI: 10.1038/s41575-022-00587-w] [Reference Citation Analysis]
9 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Reference Citation Analysis]
10 Terai K, Ishigaki K, Kagawa Y, Okada K, Yoshida O, Sakurai N, Heishima T, Asano K. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021). J Am Vet Med Assoc 2022;:1-7. [PMID: 35482569 DOI: 10.2460/javma.21.12.0514] [Reference Citation Analysis]
11 Shigematsu Y, Amori G, Kanda H, Takahashi Y, Takazawa Y, Takeuchi K, Inamura K. Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. Virchows Arch 2022. [PMID: 35459975 DOI: 10.1007/s00428-022-03318-3] [Reference Citation Analysis]
12 Chen X, Sun S, Lu Y, Shi X, Wang Z, Chen X, Han G, Zhao J, Gao Y, Wang X. Promising role of liver transplantation in patients with combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis. Ann Transl Med 2022;10:434. [PMID: 35571416 DOI: 10.21037/atm-21-5391] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang Y, Zhu GQ, Zhou CW, Li N, Yang C, Zeng MS. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. Eur Radiol 2022. [PMID: 35316365 DOI: 10.1007/s00330-022-08691-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Chen Y, Lu Q, Zhang W, Cao J, Dong Y, Wang W. Preoperative Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Nomogram Based on Ultrasonographic Features and Clinical Indicators. Front Oncol 2022;12:757774. [PMID: 35242699 DOI: 10.3389/fonc.2022.757774] [Reference Citation Analysis]
15 Wu Y, Liu H, Zeng J, Chen Y, Fang G, Zhang J, Zhou W, Zeng Y, Liu J. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study. World J Surg Onc 2022;20. [DOI: 10.1186/s12957-022-02536-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhou Y, Zhou G, Zhang J, Xu C, Zhu F, Xu P. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma. Eur Radiol 2022. [PMID: 35128572 DOI: 10.1007/s00330-022-08548-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Chen X, Lu Y, Shi X, Chen X, Rong D, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma. J Oncol 2021;2021:3002480. [PMID: 34925507 DOI: 10.1155/2021/3002480] [Reference Citation Analysis]
18 Hou GM, Jiang C, Du JP, Yuan KF. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Cancer Med 2021. [PMID: 34866356 DOI: 10.1002/cam4.4448] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Gruttadauria S, Barbera F, Pagano D, Liotta R, Miraglia R, Barbara M, Bavetta MG, Cammà C, Petridis I, Di Carlo D, Conaldi PG, Di Francesco F. Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling. Cancers (Basel) 2021;13:6049. [PMID: 34885159 DOI: 10.3390/cancers13236049] [Reference Citation Analysis]
20 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Reference Citation Analysis]
21 Childs A, Zakeri N, Ma YT, O'Rourke J, Ross P, Hashem E, Hubner RA, Hockenhull K, Iwuji C, Khan S, Palmer DH, Connor J, Swinson D, Darby S, Braconi C, Roques T, Yu D, Luong TV, Meyer T. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. Br J Cancer 2021;125:1350-5. [PMID: 34526664 DOI: 10.1038/s41416-021-01535-2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
22 Wang J, Li Z, Liao Y, Li J, Dong H, Peng H, Xu W, Fan Z, Gao F, Liu C, Liu D, Zhang Y. Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study. Front Oncol 2021;11:686972. [PMID: 34336671 DOI: 10.3389/fonc.2021.686972] [Reference Citation Analysis]
23 Sato K, Baiocchi L, Kennedy L, Zhang W, Ekser B, Glaser S, Francis H, Alpini G. Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers (Basel) 2021;13:3307. [PMID: 34282753 DOI: 10.3390/cancers13133307] [Reference Citation Analysis]
24 Han H, Lin T, Fang Z, Zhou G. RBM23 Drives Hepatocellular Carcinoma by Activating NF-κB Signaling Pathway. Biomed Res Int 2021;2021:6697476. [PMID: 33791378 DOI: 10.1155/2021/6697476] [Reference Citation Analysis]